<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313490432</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313490432</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Lupus around the world</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Borba</surname><given-names>EF</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313490432">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313490432"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Araujo</surname><given-names>DB</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313490432">1</xref>
<xref ref-type="aff" rid="aff2-0961203313490432">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bonfá</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313490432">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shinjo</surname><given-names>SK</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313490432">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203313490432"><label>1</label>Division of Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil</aff>
<aff id="aff2-0961203313490432"><label>2</label>Department of Rheumatology, Hospital do Servidor Público Estadual de São Paulo, Brazil</aff>
<author-notes>
<corresp id="corresp1-0961203313490432">Correspondence to: Samuel Katsuyuki Shinjo, Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 455, 3 andar, sala 3150, Cerqueira César, CEP 01246-903, São Paulo, Brazil. Email: <email>samuel.shinjo@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>7</issue>
<fpage>744</fpage>
<lpage>749</lpage>
<history>
<date date-type="received"><day>12</day><month>12</month><year>2012</year></date>
<date date-type="accepted"><day>20</day><month>4</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Epidemiological studies with systemic lupus erythematosus (SLE) patients have been reported worldwide but, until now, a large evaluation had not been performed in Brazil. Therefore, we determined the clinical and immunological features of 888 SLE patients followed at our service from 2008 to 2012. The mean age at SLE onset and the mean disease duration were 29.9 ± 9.5 years old and 14.5 ± 8.4 years, respectively. A predominance of female gender (91.9%) and Caucasian ethnicity (69.9%) were observed. Cumulative mucocutaneous manifestations (90.7%) were most commonly identified (malar rash (83.2%), photosensitivity (76.9%)) followed by articular (87.4%), hematological (44.0%) and renal (36.9%) involvements. Antinuclear antibody was detected in all patients, followed by anti-dsDNA (35.1%), anti-Sm (21.8%) and anti-ribosomal P protein antibodies (19.8%). Additional comparison of clinical and laboratory features between genders revealed that malar rash was observed more in female SLE patients (84.5% vs. 69.4%, <italic>p</italic> = 0.001). Male lupus patients presented a higher frequency of anti-dsDNA (45.8% vs. 34.2%, <italic>p</italic> = 0.047) and a trend of more nephritis (47.2% vs. 36.0%, <italic>p</italic> = 0.059). In conclusion, we identified a high prevalence of mucocutaneous manifestations in this Brazilian SLE cohort compared to other countries, mainly malar rash that was most commonly observed in female patients. Anti-dsDNA and other specific SLE autoantibodies were also identified in a higher frequency, predominantly in the male gender.</p>
</abstract>
<kwd-group>
<kwd>Anti-DNA</kwd>
<kwd>autoantibody</kwd>
<kwd>gender</kwd>
<kwd>malar rash</kwd>
<kwd>systemic lupus erythematosus</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313490432" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a pleomorphic systemic autoimmune disease in which the interplay of genetic, environmental and sociodemographic factors may have an important role in the SLE pathogenesis. Clinical and immunological features among several ethnic SLE populations have been described<sup><xref ref-type="bibr" rid="bibr1-0961203313490432">1</xref><xref ref-type="bibr" rid="bibr2-0961203313490432"/>–<xref ref-type="bibr" rid="bibr3-0961203313490432">3</xref></sup> to determine distinctive disease subtypes that may allow SLE recognition and better patient management.</p>
<p>There is substantial evidence that geographical variations could determine different SLE characteristics, including frequency of organ involvement and immunological findings, that could determine disease prognosis.<sup><xref ref-type="bibr" rid="bibr4-0961203313490432">4</xref></sup> In fact, cutaneous involvement has been described at high frequencies in countries in tropical areas, including Brazil, due to the exposure to ultraviolet light.<sup><xref ref-type="bibr" rid="bibr5-0961203313490432">5</xref>,<xref ref-type="bibr" rid="bibr6-0961203313490432">6</xref></sup></p>
<p>Brazil is a continental country that includes tropical and temperate zones, but sunlight is present during most of the seasons in all Brazilian territories, with ultraviolet light indexes ranging from low to extremely high levels. Because of the high exposure to ultraviolet light, Brazilian lupus patients are expected to have a high frequency of cutaneous manifestations, which may be one of the reasons for the high SLE incidence found in our country.<sup><xref ref-type="bibr" rid="bibr5-0961203313490432">5</xref>,<xref ref-type="bibr" rid="bibr7-0961203313490432">7</xref></sup> Most of the studies previously performed in our country had a small number of patients or low information that hampers a definitive conclusion about this issue.</p>
<p>Therefore, we performed a complete clinical and laboratory evaluation in a large sample of lupus patients from a single tertiary center to determine the main features of the Brazilian SLE population compared to those of other countries.</p>
</sec>
<sec id="sec2-0961203313490432" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0961203313490432"><title>Patient selection</title>
<p>During the period from January 2008 to January 2012, 888 patients with adult SLE onset (≥18 years old) fulfilling four or more criteria of the revised American College of Rheumatology (ACR) criteria for SLE<sup><xref ref-type="bibr" rid="bibr8-0961203313490432">8</xref></sup> and regularly followed in our Lupus Clinics at Rheumatology Division were included. Our hospital is a tertiary rheumatology referral center located in São Paulo (Southeast, Brazil) and receives patients from all Brazilian regions. Data were obtained from the ongoing electronic database protocol carried out for all SLE patients at one- to six-month intervals that consists of an extensive clinical and laboratory evaluation, including those relevant for this study. The study was approved by the local ethics committee.</p>
</sec>
<sec id="sec4-0961203313490432"><title>Demographic data</title>
<p>SLE onset was defined at the time of the diagnosis according to classification criteria.<sup><xref ref-type="bibr" rid="bibr8-0961203313490432">8</xref></sup> Clinical and serological findings were recorded (present or absent) for each lupus patient at entry and during the disease course. The SLE clinical manifestations were defined as: mucocutaneous disease (malar or discoid rash, mucosal ulcers or photosensitivity), renal involvement (proteinuria ≥ 0.5 g/24 hours, presence of cellular casts, hematuria with &gt; 10 red blood cells/high-power field (hpf) excluding infection or stone, &gt;5/hpf leukocytes excluding infection and plasma creatinine ≥ 1.4 mg %), articular involvement (non-erosive arthritis involving two or more peripheral joints), neuropsychiatric disease (psychosis, seizure), serositis (pleuritis, pericarditis) and hematologic complications (autoimmune hemolytic anemia with reticulocytosis, leukopenia with a white blood cell count &lt; 4000/mm<sup>3</sup> or lymphopenia &lt; 1500/mm<sup>3</sup> on two or more occasions and thrombocytopenia with platelet count &lt; 100000/mm<sup>3</sup> in the absence of drugs were noted).</p>
</sec>
<sec id="sec5-0961203313490432"><title>Serological studies</title>
<p>A regular autoantibody assessment is regularly performed for each lupus patient during follow-up per our ongoing electronic database protocol. Immunological evaluation included antinuclear antibodies (ANA) and autoantibodies detection. ANA was detected by indirect immunofluorescence technique using HEp-2 cells as substrate. Anti-double-stranded DNA (anti-dsDNA) was also detected by indirect immunofluorescence using <italic>Crithidia luciliae</italic> as substrate. A hemagglutination assay with rabbit thymus extract was used to determine the presence of antibodies to RNP and Sm proteins.<sup><xref ref-type="bibr" rid="bibr9-0961203313490432">9</xref></sup> Detection of autoantibodies to saline-soluble antigens, Ro/SS-A and La/SS-B, was performed by counterimmunoelectrophoresis against dog spleen saline extract.<sup><xref ref-type="bibr" rid="bibr10-0961203313490432">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203313490432">11</xref></sup> Nonspecific reference sera were included in each assay to characterize autoantibody specificity. Presence of anticardiolipin antibodies (aCL) IgG and IgM was analyzed by enzyme-linked immunosorbent assay (ELISA).<sup><xref ref-type="bibr" rid="bibr12-0961203313490432">12</xref></sup> Lupus anticoagulant (LA) was detected according to the guidelines of the International Society on Thrombosis and Hemostasis.<sup><xref ref-type="bibr" rid="bibr13-0961203313490432">13</xref></sup> The anti-ribosomal P protein antibodies were detected by Western blotting technique using purified ribosomal fraction isolated from rat hepatocytes as substrate.<sup><xref ref-type="bibr" rid="bibr14-0961203313490432">14</xref></sup></p>
</sec>
<sec id="sec6-0961203313490432"><title>Statistical analysis</title>
<p>Results are expressed as mean ± standard deviation (SD) or percentage. Statistical analysis employed the Student’s <italic>t</italic> test for parametric data, chi square test for categorical data. These calculations were conducted with the computer program STATA version 7.0 (STATA, College Station, TX, USA). <italic>P</italic> values &lt; 0.05 were considered to be statistically significant.</p>
</sec>
</sec>
<sec id="sec7-0961203313490432" sec-type="results"><title>Results</title>
<sec id="sec8-0961203313490432"><title>Demographical data</title>
<p>The demographical and clinical data of the 888 adult SLE patients and those of other previous studies are illustrated in <xref ref-type="table" rid="table1-0961203313490432">Table 1</xref>.
<table-wrap id="table1-0961203313490432" position="float"><label>Table 1</label><caption><p>Demographical and clinical features of the 888 Brazilian adults with systemic lupus erythematosus</p></caption>
<graphic alternate-form-of="table1-0961203313490432" xlink:href="10.1177_0961203313490432-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Brazil</th>
<th>North America</th>
<th>Europe</th>
<th>Brazil</th>
<th>Spain</th>
<th>Puerto Rico</th>
<th colspan="3">Latin America</th>
<th colspan="2">LUMINA (Hispanics)</th>
<th>Portugal</th>
</tr></thead>
<tbody align="left">
<tr>
<td>References</td>
<td><sup><xref ref-type="table-fn" rid="table-fn1-0961203313490432">a</xref></sup></td>
<td><sup>17</sup></td>
<td><sup><xref ref-type="bibr" rid="bibr20-0961203313490432">20</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr18-0961203313490432">18</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr6-0961203313490432">6</xref></sup></td>
<td colspan="3"><sup><xref ref-type="bibr" rid="bibr21-0961203313490432">21</xref></sup></td>
<td colspan="2"><sup><xref ref-type="bibr" rid="bibr22-0961203313490432">22</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr19-0961203313490432">19</xref></sup></td>
</tr>
<tr>
<td>Year</td>
<td>2012</td>
<td>1991</td>
<td>1993</td>
<td>1995</td>
<td>1995</td>
<td>1999</td>
<td>2004</td>
<td colspan="2">2004</td>
<td>2007</td>
</tr>
<tr>
<td>European</td>
<td>Mestizo</td>
<td>African</td>
<td>Tex</td>
<td>Puerto Rican</td>
</tr>
<tr>
<td>Number of patients</td>
<td>888</td>
<td>464</td>
<td>1000</td>
<td>685</td>
<td>307</td>
<td>124</td>
<td>507</td>
<td>537</td>
<td>152</td>
<td>105</td>
<td>81</td>
<td>544</td>
</tr>
<tr>
<td>Age at SLE onset ± SD (yrs)</td>
<td>29.9 ± 9.5</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>32 ± 12</td>
<td>31.1</td>
<td>29.9</td>
<td>26.9</td>
<td>—</td>
<td>—</td>
<td>34.9 ± 15.4</td>
</tr>
<tr>
<td>SLE duration ± SD (yrs)</td>
<td>14.5 ± 8.4</td>
<td>6</td>
<td>8.4</td>
<td>—</td>
<td>—</td>
<td>7.4 ± 6.0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1.4 ± 1.4</td>
<td>1.7 ± 1.3</td>
<td>—</td>
</tr>
<tr>
<td>Female:male rate</td>
<td>11.3 : 1</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>8.6 : 1</td>
<td>18 : 1</td>
<td>9.8 : 1</td>
<td>8.1 : 1</td>
<td>8.5 : 1</td>
<td>12.1 : 1</td>
<td>19.3 : 1</td>
<td>13 : 1</td>
</tr>
<tr>
<td>Malar rash (%)</td>
<td>83.2</td>
<td>34</td>
<td>31.1</td>
<td>51</td>
<td>58</td>
<td>71.9</td>
<td>63.3</td>
<td>59</td>
<td>63.2</td>
<td>45.7</td>
<td>65.4</td>
<td>45</td>
</tr>
<tr>
<td>Discoid rash (%)</td>
<td>8.2</td>
<td>23</td>
<td>7.8</td>
<td>9</td>
<td>—</td>
<td>—</td>
<td>11.2</td>
<td>10.4</td>
<td>19.7</td>
<td>2.9</td>
<td>13.6</td>
<td>9</td>
</tr>
<tr>
<td>Photosensitivity (%)</td>
<td>76.9</td>
<td>37</td>
<td>22.9</td>
<td>47</td>
<td>46</td>
<td>76.9</td>
<td>59.8</td>
<td>51.8</td>
<td>59.2</td>
<td>41</td>
<td>81.5</td>
<td>52</td>
</tr>
<tr>
<td>Oral ulcers (%)</td>
<td>23.2</td>
<td>19</td>
<td>12.5</td>
<td>—</td>
<td>—</td>
<td>30</td>
<td>40.6</td>
<td>43.2</td>
<td>40.1</td>
<td>38.1</td>
<td>32.1</td>
<td>45</td>
</tr>
<tr>
<td>Arthritis (%)</td>
<td>87.4</td>
<td>91</td>
<td>48.1</td>
<td>82</td>
<td>83</td>
<td>67.5</td>
<td>93.5<sup>b</sup></td>
<td>92.5<sup>b</sup></td>
<td>94.1<sup>b</sup></td>
<td>79.1</td>
<td>69.1</td>
<td>72</td>
</tr>
<tr>
<td>Serositis (%) Pleurisies (%) Pericarditis (%)</td>
<td>26.7 18.7 10.9</td>
<td>—</td>
<td>—</td>
<td>24</td>
<td>48</td>
<td>28</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>60</td>
<td>8.6</td>
<td>25</td>
</tr>
<tr>
<td>Renal (%)</td>
<td>36.9</td>
<td>31</td>
<td>27.9</td>
<td>52</td>
<td>42</td>
<td>30</td>
<td>43.6</td>
<td>58.3</td>
<td>55.3</td>
<td>41</td>
<td>13.6</td>
<td>37</td>
</tr>
<tr>
<td>Neurological (%)</td>
<td>9.7</td>
<td>19.4</td>
<td>13</td>
<td>15</td>
<td>2</td>
<td>26.4</td>
<td>27.7</td>
<td>21.7</td>
<td>—</td>
<td>—</td>
<td>18</td>
</tr>
<tr>
<td>Seizure (%)</td>
<td>1.6</td>
<td>6</td>
<td>—</td>
<td>—</td>
<td>10</td>
<td>2</td>
<td>7.9</td>
<td>8.6</td>
<td>6.6</td>
<td>4.8</td>
<td>2.5</td>
<td>5</td>
</tr>
<tr>
<td>Psychosis (%)</td>
<td>8.1</td>
<td>5</td>
<td>—</td>
<td>—</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>5.2</td>
<td>3.9</td>
<td>5.7</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Hematological (%)</td>
<td>44.0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>58</td>
</tr>
<tr>
<td>Hemolytic anemia (%)</td>
<td>8.7</td>
<td>8</td>
<td>4.8</td>
<td>–</td>
<td>9</td>
<td>13</td>
<td>13</td>
<td>11.5</td>
<td>9.9</td>
<td>8.6</td>
<td>3.7</td>
<td>13</td>
</tr>
<tr>
<td>Leukopenia (%)</td>
<td>18.5</td>
<td>51</td>
<td>—</td>
<td>—</td>
<td>58</td>
<td>42</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>26.7</td>
<td>33.3</td>
<td>36</td>
</tr>
<tr>
<td>Lymphopenia (%)</td>
<td>26.1</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>60</td>
<td>65</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>61.9</td>
<td>54.3</td>
<td>30</td>
</tr>
<tr>
<td>Thrombocytopenia (%)</td>
<td>14.5</td>
<td>16</td>
<td>13.4</td>
<td>—</td>
<td>19</td>
<td>19</td>
<td>19.1</td>
<td>18.2</td>
<td>23</td>
<td>21</td>
<td>3.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313490432"><p>SD: standard deviation; SLE: systemic lupus erythematosus; yrs: years. <sup>a</sup>Present study. <sup>b</sup>Arthralgia or arthritis.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The present study with Brazilian SLE patients is one of the largest reported. The mean age at SLE onset observed herein was 29.9 ± 9.5 years old with mean disease duration of 14.5 ± 8.4 years, which are comparable to those of previous studies. More than two-thirds of the SLE patients were self-defined as Caucasian (69.9%). There was a predominance of female gender (91.9%) with a rate of 816 females and 72 males (11.3 : 1) that was within the range of other cohorts (8.1 : 1 to 19.3 : 1) (<xref ref-type="table" rid="table1-0961203313490432">Table 1</xref>).</p>
</sec>
<sec id="sec9-0961203313490432"><title>Clinical manifestations</title>
<p>The mucocutaneous manifestation was the most common feature observed in the present cohort (90.7%). Malar rash and photosensitivity were identified in a high frequency (83.2% and 76.9%, respectively) compared to those of other studies and comparable only to those observed in Puerto Rico (<xref ref-type="table" rid="table1-0961203313490432">Table 1</xref>).</p>
<p>Articular was the second most common involvement of our cohort, observed in 776 patients (87.4%). Hematological manifestations were identified in 391 SLE patients (44.0%) and included lymphopenia (26.1%), leukopenia (18.5%), thrombocytopenia (14.5%) and autoimmune hemolytic anemia (8.7%).</p>
<p>Renal involvement was observed in more than one-third of our patients (36.9%) and was within the range (27.9% to 58.3%) of other studies. The frequency of serositis in our SLE patients was 26.7%, and a clear predominance of pleurisies (18.7%) was observed when compared to pericarditis (10.9%).</p>
<p>Neuropsychiatric manifestations were identified in 9.7% of our cohort and included seizures and psychosis (1.6% and 8.1%, respectively).</p>
</sec>
<sec id="sec10-0961203313490432"><title>Immunological features</title>
<p>Immunological findings of our cohort SLE patients as well as those from other previous studies are summarized in <xref ref-type="table" rid="table2-0961203313490432">Table 2</xref>. Anti-dsDNA antibodies were detected in more than one-third of our patients (35.1%), the lowest frequency compared to other studies (<xref ref-type="table" rid="table2-0961203313490432">Table 2</xref>). Regarding other specific SLE antibodies, anti-Sm was detected in 21.8%, a frequency quite similar to that identified for anti-ribosomal P protein (19.8%), which were routinely assessed in our lupus patients. Anti-Ro/SSA antibodies were detected in 31.6%, almost four times greater than the frequency observed for anti-La/SSB (7.0%), whereas aCL (IgG and IgM) and LA were observed in 13.0% and 5.5%, respectively.
<table-wrap id="table2-0961203313490432" position="float"><label>Table 2</label><caption><p>Immunological features of the 888 Brazilian adults with systemic lupus erythematosus</p></caption>
<graphic alternate-form-of="table2-0961203313490432" xlink:href="10.1177_0961203313490432-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Brazil</th>
<th>North America</th>
<th>Europe</th>
<th>Brazil</th>
<th>Spain</th>
<th>Puerto Rico</th>
<th colspan="3">Latin America</th>
<th colspan="2">LUMINA (Hispanics)</th>
<th>Portugal</th>
</tr></thead>
<tbody align="left">
<tr>
<td>References</td>
<td><sup><xref ref-type="table-fn" rid="table-fn2-0961203313490432">a</xref></sup></td>
<td><sup>17</sup></td>
<td><sup><xref ref-type="bibr" rid="bibr20-0961203313490432">20</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr18-0961203313490432">18</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr6-0961203313490432">6</xref></sup></td>
<td colspan="3"><sup><xref ref-type="bibr" rid="bibr21-0961203313490432">21</xref></sup></td>
<td colspan="2"><sup><xref ref-type="bibr" rid="bibr22-0961203313490432">22</xref></sup></td>
<td><sup><xref ref-type="bibr" rid="bibr19-0961203313490432">19</xref></sup></td>
</tr>
<tr>
<td>Year</td>
<td>2012</td>
<td>1991</td>
<td>1993</td>
<td>1995</td>
<td>1995</td>
<td>1999</td>
<td colspan="3">2004</td>
<td colspan="2">2004</td>
<td>2007</td>
</tr>
<tr>
<td>European</td>
<td>Mestizo</td>
<td>Tex</td>
<td>Puerto Rican</td>
</tr>
<tr>
<td>Anti-dsDNA (%)</td>
<td>35.1</td>
<td>40</td>
<td>78</td>
<td>47</td>
<td>76</td>
<td>54.5</td>
<td>67.2</td>
<td>74.6</td>
<td>—</td>
<td>69.5</td>
<td>46.9</td>
<td>—</td>
</tr>
<tr>
<td>Anti-Sm (%)</td>
<td>21.8</td>
<td>6</td>
<td>10</td>
<td>43</td>
<td>11</td>
<td>15.9</td>
<td>47.1</td>
<td>48.8</td>
<td>—</td>
<td>26.7</td>
<td>16.1</td>
<td>—</td>
</tr>
<tr>
<td>Anti-ribosomal P protein (%)</td>
<td>19.8</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Anti-RNP (%)</td>
<td>38.4</td>
<td>14</td>
<td>13</td>
<td>—</td>
<td>23</td>
<td>18.9</td>
<td>49.3</td>
<td>54.2</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Anti-Ro/SS-A (%)</td>
<td>31.6</td>
<td>19</td>
<td>25</td>
<td>—</td>
<td>28</td>
<td>30.1</td>
<td>50.2</td>
<td>46.5</td>
<td>—</td>
<td>11.4</td>
<td>24.7</td>
<td>—</td>
</tr>
<tr>
<td>Anti-La/SS-B (%)</td>
<td>7.0</td>
<td>—</td>
<td>19</td>
<td>—</td>
<td>9</td>
<td>14.2</td>
<td>26.1</td>
<td>31.4</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Lupic anticoagulant (%)</td>
<td>5.5</td>
<td>—</td>
<td>15</td>
<td>—</td>
<td>—</td>
<td>9.5</td>
<td>38.1</td>
<td>24.7</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Anticardiolipin IgG (%)</td>
<td rowspan="2">7.2 5.8</td>
<td>—</td>
<td>24</td>
<td>—</td>
<td>—</td>
<td>33.0</td>
<td>55.0</td>
<td>48.7</td>
<td>—</td>
<td>18.1</td>
<td>14.8</td>
<td>—</td>
</tr>
<tr>
<td>Anticardiolpin IgM (%)</td>
<td>—</td>
<td>13</td>
<td>—</td>
<td>—</td>
<td>19.2</td>
<td>41.4</td>
<td>42.6</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Antinuclear antibody (%)</td>
<td>100</td>
<td>—</td>
<td>96</td>
<td>96</td>
<td>100</td>
<td>93.3</td>
<td>99.4</td>
<td>95.9</td>
<td>—</td>
<td>97.1</td>
<td>93.8</td>
<td>—</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203313490432"><label>a</label><p>Present study.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec11-0961203313490432"><title>Male vs. female comparison</title>
<p>Clinical and immunological data according to gender of our adult SLE patients are illustrated in <xref ref-type="table" rid="table3-0961203313490432">Table 3</xref>. The mean age at disease onset of female patients was comparable to that of the male patients, and no significant difference was observed in their distribution along the decades. Mean disease duration was also similar between groups (<xref ref-type="table" rid="table3-0961203313490432">Table 3</xref>). Regarding clinical manifestations, a significant higher frequency of malar rash was observed in female gender (84.5% vs. 69.4%, <italic>p</italic> = 0.001). In contrast, the male lupus patients had a trend of more nephritis (47.2% vs. 36.0%, <italic>p</italic> = 0.059) compared to female patients. No other significant differences were observed between groups in the frequency of other clinical manifestations. Regarding immunological findings, a significant higher frequency of anti-dsDNA antibodies was detected in male patients compared to female patients (45.8% vs. 34.2%, <italic>p</italic> = 0.047). No other significant differences were observed between groups in the frequency of all the other antibodies.
<table-wrap id="table3-0961203313490432" position="float"><label>Table 3</label><caption><p>Characteristics of the 888 Brazilian adults with systemic lupus erythematosus according to gender</p></caption>
<graphic alternate-form-of="table3-0961203313490432" xlink:href="10.1177_0961203313490432-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Male (<italic>n</italic> = 72)</th>
<th>Female (<italic>n</italic> = 816)</th>
<th><italic>p</italic></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age at disease onset ± SD, yrs</td>
<td>29.9 ± 10.4</td>
<td>29.9 ± 9.5</td>
<td>0.984</td>
</tr>
<tr>
<td>18 to 23 yrs (%)</td>
<td>26 (36.1)</td>
<td>242 (29.7)</td>
<td rowspan="4">0.493</td>
</tr>
<tr>
<td>24 to 28 yrs (%)</td>
<td>14 (19.4)</td>
<td>183 (22.4)</td>
</tr>
<tr>
<td>29 to 35 yrs (%)</td>
<td>13 (18.1)</td>
<td>197 (24.1)</td>
</tr>
<tr>
<td>36 to 66 yrs (%)</td>
<td>19 (26.4)</td>
<td>194 (23.8)</td>
</tr>
<tr>
<td>Disease duration ± SD, yrs</td>
<td>14.7 ± 8.7</td>
<td>13.8 ± 8.8</td>
<td>0.687</td>
</tr>
<tr>
<td>Clinical manifestations</td>
</tr>
<tr>
<td>Rash malar (%)</td>
<td>50 (69.4)</td>
<td>689 (84.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>Discoid lupus (%)</td>
<td>6 (8.3)</td>
<td>46 (5.6)</td>
<td>0.390</td>
</tr>
<tr>
<td>Photosensitivity (%)</td>
<td>54 (75.0)</td>
<td>629 (77.1)</td>
<td>0.688</td>
</tr>
<tr>
<td>Oral ulcers (%)</td>
<td>11 (15.3)</td>
<td>195 (23.9)</td>
<td>0.097</td>
</tr>
<tr>
<td>Arthritis (%)</td>
<td>64 (88.9)</td>
<td>712 (87.3)</td>
<td>0.689</td>
</tr>
<tr>
<td>Serositis (%)</td>
<td>22 (30.6)</td>
<td>215 (26.4)</td>
<td>0.439</td>
</tr>
<tr>
<td>Pleurisies (%)</td>
<td>18 (25.0)</td>
<td>148 (18.1)</td>
<td>0.152</td>
</tr>
<tr>
<td>Pericarditis (%)</td>
<td>8 (11.1)</td>
<td>89 (10.9)</td>
<td>0.958</td>
</tr>
<tr>
<td>Renal involvement (%)</td>
<td>34 (47.2)</td>
<td>294 (36.0)</td>
<td>0.059</td>
</tr>
<tr>
<td>Neurological involvement (%)</td>
<td>6 (8.3)</td>
<td>80 (9.8)</td>
<td>0.686</td>
</tr>
<tr>
<td>Psychosis (%)</td>
<td>5 (6.9)</td>
<td>67 (8.2)</td>
<td>1.000</td>
</tr>
<tr>
<td>Seizure (%)</td>
<td>1 (1.4)</td>
<td>13 (1.6)</td>
<td>1.000</td>
</tr>
<tr>
<td>Hematological involvement (%)</td>
<td>34 (47.2)</td>
<td>357 (43.8)</td>
<td>0.569</td>
</tr>
<tr>
<td>Hemolytic anemia (%)</td>
<td>4 (5.6)</td>
<td>73 (9.0)</td>
<td>0.327</td>
</tr>
<tr>
<td>Leukopenia (%)</td>
<td>13 (18.1)</td>
<td>151 (18.5)</td>
<td>0.925</td>
</tr>
<tr>
<td>Lymphopenia (%)</td>
<td>22 (30.6)</td>
<td>210 (25.7)</td>
<td>0.372</td>
</tr>
<tr>
<td>Thrombocytopenia (%)</td>
<td>11 (15.3)</td>
<td>118 (14.5)</td>
<td>0.850</td>
</tr>
<tr>
<td>Immunological features</td>
</tr>
<tr>
<td>Anti-dsDNA (%)</td>
<td>33 (45.8)</td>
<td>279 (34.2)</td>
<td>0.047</td>
</tr>
<tr>
<td>Anti-Sm (%)</td>
<td>21 (29.2)</td>
<td>173 (21.2)</td>
<td>0.117</td>
</tr>
<tr>
<td>Anti-ribosomal P protein (%)</td>
<td>12 (16.7)</td>
<td>164 (20.1)</td>
<td>0.484</td>
</tr>
<tr>
<td>Anti-ENA (%)</td>
<td>29 (40.3)</td>
<td>302 (37.0)</td>
<td>0.582</td>
</tr>
<tr>
<td>Anti-Ro/SS-A (%)</td>
<td>24 (33.3)</td>
<td>257 (31.5)</td>
<td>0.748</td>
</tr>
<tr>
<td>Anti-La/SS-B (%)</td>
<td>7 (9.7)</td>
<td>55 (6.7)</td>
<td>0.341</td>
</tr>
<tr>
<td>Lupic anticoagulant (%)</td>
<td>4 (5.5)</td>
<td>45 (5.5)</td>
<td>0.988</td>
</tr>
<tr>
<td>Anticardiolipin IgG (%)</td>
<td>6 (8.3)</td>
<td>58 (7.1)</td>
<td>0.700</td>
</tr>
<tr>
<td>Anticardiolipin IgM (%)</td>
<td>3 (4.2)</td>
<td>48 (5.9)</td>
<td>0.549</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203313490432"><p>SD: standard deviation; yrs: years.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec12-0961203313490432" sec-type="discussion"><title>Discussion</title>
<p>This is the largest cohort study of a single center in our country that describes the main epidemiological, clinical and laboratory features of Brazilian SLE patients, and it clearly identified that malar rash is a frequent cutaneous manifestation in our patients. Although not completely representing all regions of our country, it allows the comparison of these SLE characteristics with those observed in other studies worldwide.</p>
<p>This study was designed to define the main characteristics of our SLE patients and has the advantage of including Brazilian patients from a lupus clinic of a single center in São Paulo. Although our hospital is a tertiary rheumatology referral center in the Southeast region of Brazil and receives patients from other regions, it did not recognize the real prevalence of SLE in our country. Indeed, the prevalence of SLE is not precisely determined in Brazil, as only one study detected an annual incidence of 8.4/100000 habitants in a city in the Northeastern region of our country.<sup><xref ref-type="bibr" rid="bibr5-0961203313490432">5</xref></sup> It suggested an estimated prevalence around 0.098%;<sup><xref ref-type="bibr" rid="bibr15-0961203313490432">15</xref></sup> worldwide prevalence varies from 14.6 to 122 cases/100,000 habitants.<sup><xref ref-type="bibr" rid="bibr7-0961203313490432">7</xref></sup></p>
<p>Moreover, the present study clearly recognized that the great majority of Brazilian SLE patients were women and identified a female to male ratio of 11.3 : 1, as expected throughout the world. Indeed, this finding confirms those observed previously in other epidemiological studies<sup><xref ref-type="bibr" rid="bibr6-0961203313490432">6</xref>,<xref ref-type="bibr" rid="bibr16-0961203313490432">16</xref><xref ref-type="bibr" rid="bibr17-0961203313490432"/><xref ref-type="bibr" rid="bibr18-0961203313490432"/><xref ref-type="bibr" rid="bibr19-0961203313490432"/><xref ref-type="bibr" rid="bibr20-0961203313490432"/><xref ref-type="bibr" rid="bibr21-0961203313490432"/><xref ref-type="bibr" rid="bibr22-0961203313490432"/><xref ref-type="bibr" rid="bibr23-0961203313490432"/><xref ref-type="bibr" rid="bibr24-0961203313490432"/><xref ref-type="bibr" rid="bibr25-0961203313490432"/><xref ref-type="bibr" rid="bibr26-0961203313490432"/><xref ref-type="bibr" rid="bibr27-0961203313490432"/><xref ref-type="bibr" rid="bibr28-0961203313490432"/>–<xref ref-type="bibr" rid="bibr29-0961203313490432">29</xref></sup> that demonstrated ratios ranging from 8.1 : 1 to 19.3 : 1.<sup><xref ref-type="bibr" rid="bibr17-0961203313490432">17</xref><xref ref-type="bibr" rid="bibr18-0961203313490432"/><xref ref-type="bibr" rid="bibr19-0961203313490432"/><xref ref-type="bibr" rid="bibr20-0961203313490432"/><xref ref-type="bibr" rid="bibr21-0961203313490432"/><xref ref-type="bibr" rid="bibr22-0961203313490432"/>–<xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref>,<xref ref-type="bibr" rid="bibr30-0961203313490432">30</xref></sup> In addition, it also confirms that disease onset occurs between the second and third decade, which has also been previously documented in other countries.<sup><xref ref-type="bibr" rid="bibr16-0961203313490432">16</xref><xref ref-type="bibr" rid="bibr17-0961203313490432"/><xref ref-type="bibr" rid="bibr18-0961203313490432"/><xref ref-type="bibr" rid="bibr19-0961203313490432"/><xref ref-type="bibr" rid="bibr20-0961203313490432"/><xref ref-type="bibr" rid="bibr21-0961203313490432"/><xref ref-type="bibr" rid="bibr22-0961203313490432"/><xref ref-type="bibr" rid="bibr23-0961203313490432"/><xref ref-type="bibr" rid="bibr24-0961203313490432"/><xref ref-type="bibr" rid="bibr25-0961203313490432"/><xref ref-type="bibr" rid="bibr26-0961203313490432"/><xref ref-type="bibr" rid="bibr27-0961203313490432"/><xref ref-type="bibr" rid="bibr28-0961203313490432"/><xref ref-type="bibr" rid="bibr29-0961203313490432"/>–<xref ref-type="bibr" rid="bibr30-0961203313490432">30</xref></sup> Importantly, our findings are similar to those observed in the largest multicenter European casuistic<sup><xref ref-type="bibr" rid="bibr20-0961203313490432">20</xref></sup> that identified a mean age at diagnosis of 31 ± 13 years old with a female to male ratio of 9.9 : 1, and was also comparable to the Latin American cohort (Grupo Latinoamericano de Estudio del Lupus (GLADEL) cohort)<sup><xref ref-type="bibr" rid="bibr21-0961203313490432">21</xref></sup> that described a mean age at disease onset of 28 ± 12 years old with a female to male ratio of 9.8 : 1.</p>
<p>Our SLE patients were predominantly Caucasian; however, it should be remembered that skin-color classification is very subjective in Brazil, where miscegenation rates are high.<sup><xref ref-type="bibr" rid="bibr31-0961203313490432">31</xref></sup> Most of the population of Southeast Brazilian is composed of European descendants, and this tropical and temperate zone is exposed to sunlight during most of the seasons. These observations might explain the higher prevalence of malar rash and photosensitivity identified herein compared to that described in cohorts from Europe<sup><xref ref-type="bibr" rid="bibr18-0961203313490432">18</xref><xref ref-type="bibr" rid="bibr19-0961203313490432"/>–<xref ref-type="bibr" rid="bibr20-0961203313490432">20</xref></sup> and North America,<sup><xref ref-type="bibr" rid="bibr17-0961203313490432">17</xref>,<xref ref-type="bibr" rid="bibr22-0961203313490432">22</xref></sup> and similar to the frequency observed in Puerto Rico.<sup><xref ref-type="bibr" rid="bibr6-0961203313490432">6</xref>,<xref ref-type="bibr" rid="bibr22-0961203313490432">22</xref></sup> In a previous Brazilian study,<sup><xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref></sup> a prevalence of malar rash and photosensitivity (51% and 47%) was lower than reported herein, probably because of the method of data retrieval as pointed out by these authors.<sup><xref ref-type="bibr" rid="bibr26-0961203313490432">26</xref></sup> On the other hand, another study in Brazil<sup><xref ref-type="bibr" rid="bibr5-0961203313490432">5</xref></sup> described a high prevalence of cutaneous manifestations leading a high incidence of the disease in our country due to the great amount of sunlight exposure.<sup><xref ref-type="bibr" rid="bibr5-0961203313490432">5</xref></sup></p>
<p>Interestingly, a higher frequency of malar rash and photosensitivity was identified herein in female lupus patients compared to males, which might suggest a specific attribute of SLE in the former since both would be equally exposed to sunlight. Indeed, the highest female to male rates were observed in both studies of Puerto Rico SLE patients, which also demonstrated a high frequency of cutaneous manifestations and low frequency of renal disease.<sup><xref ref-type="bibr" rid="bibr6-0961203313490432">6</xref>,<xref ref-type="bibr" rid="bibr22-0961203313490432">22</xref></sup> In fact, this observation was also identified herein, as our female patients also seem to have less nephritis and anti-dsDNA than males. Moreover, men with lupus were prone to more severe disease, including renal manifestations.<sup><xref ref-type="bibr" rid="bibr32-0961203313490432">32</xref>,<xref ref-type="bibr" rid="bibr33-0961203313490432">33</xref></sup> Furthermore, the prevalence of renal involvement in about two-thirds of lupus patients in our cohort was comparable to that of most of the previous epidemiological studies, including the GLADEL cohort and the other Brazilian study.<sup><xref ref-type="bibr" rid="bibr18-0961203313490432">18</xref>,<xref ref-type="bibr" rid="bibr20-0961203313490432">20</xref><xref ref-type="bibr" rid="bibr21-0961203313490432"/><xref ref-type="bibr" rid="bibr22-0961203313490432"/>–<xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref></sup></p>
<p>As expected, articular involvement was the second most common manifestation in our cohort since this was also observed in most of the studies in SLE.<sup><xref ref-type="bibr" rid="bibr17-0961203313490432">17</xref><xref ref-type="bibr" rid="bibr18-0961203313490432"/>–<xref ref-type="bibr" rid="bibr19-0961203313490432">19</xref>,<xref ref-type="bibr" rid="bibr21-0961203313490432">21</xref><xref ref-type="bibr" rid="bibr22-0961203313490432"/>–<xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref></sup> The prevalence of arthritis in our lupus patients was 87.4%, higher than that reported in the European cohort<sup><xref ref-type="bibr" rid="bibr20-0961203313490432">20</xref></sup> but lower compared to the GLADEL cohort.<sup><xref ref-type="bibr" rid="bibr21-0961203313490432">21</xref></sup> In addition, serositis was observed in more than a quarter of our lupus patients and was within the range of 8.6% to 60% in several studies.<sup><xref ref-type="bibr" rid="bibr17-0961203313490432">17</xref><xref ref-type="bibr" rid="bibr18-0961203313490432"/><xref ref-type="bibr" rid="bibr19-0961203313490432"/><xref ref-type="bibr" rid="bibr20-0961203313490432"/><xref ref-type="bibr" rid="bibr21-0961203313490432"/><xref ref-type="bibr" rid="bibr22-0961203313490432"/>–<xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref></sup></p>
<p>Regarding immunological features, our Brazilian population demonstrated a low prevalence of specific SLE autoantibodies. In fact, the frequency of anti-dsDNA in this cohort was the lowest compared to other studies,<sup><xref ref-type="bibr" rid="bibr17-0961203313490432">17</xref><xref ref-type="bibr" rid="bibr18-0961203313490432"/><xref ref-type="bibr" rid="bibr19-0961203313490432"/><xref ref-type="bibr" rid="bibr20-0961203313490432"/><xref ref-type="bibr" rid="bibr21-0961203313490432"/><xref ref-type="bibr" rid="bibr22-0961203313490432"/>–<xref ref-type="bibr" rid="bibr23-0961203313490432">23</xref></sup> which could be explained by the use herein of a more specific method (indirect immunofluorescence using <italic>Crithidia luciliae</italic> as substrate) instead of other methods used in other cohorts. However, the frequency of anti-Sm observed in this study (21.8%) was within the range of most of the studies (6% to 48.8%), as well as the other autoantibodies.</p>
<p>Furthermore, in the present study we established the frequency of the real anti-ribosomal P protein antibodies since they were routinely performed for each lupus patient during follow-up. It is well known that these antibodies fluctuate according to disease activity such as anti-dsDNA and are also considered to be highly specific for SLE such as anti-Sm and anti-dsDNA.<sup><xref ref-type="bibr" rid="bibr34-0961203313490432">34</xref><xref ref-type="bibr" rid="bibr35-0961203313490432"/>–<xref ref-type="bibr" rid="bibr36-0961203313490432">36</xref></sup> Probably because of this behavior, their prevalence has not been systematically described. Using a specific assay for their detection, this cohort identified for the first time that almost 20% of our SLE patients had this antibody, confirming its usefulness in the diagnosis of the disease.</p>
<p>In conclusion, this is the largest cohort study of a single center in Brazil that, although it does not represent all regions of our continental country, allows the comparison of the main SLE features with other studies worldwide. In this regard, our study identified a high prevalence of mucocutaneous manifestations, mainly malar rash that was more commonly observed in female than male patients. Moreover, a higher anti-dsDNA frequency was found in males than females. The other clinical and immunological features were comparable between the present study and others.</p>
</sec>
</body>
<back>
<sec id="sec13-0961203313490432"><title>Funding</title>
<p>This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ grants #306963/2011-6 to EFB and #301411/2009-3 to EB) and Federico Foundation Grant (to EFB, EB and SKS).</p>
</sec>
<sec id="sec14-0961203313490432"><title>Conflict of interest statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313490432"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JA</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>1994</year>; <volume>330</volume>: <fpage>1871</fpage>–<lpage>1879</lpage>.</citation></ref>
<ref id="bibr2-0961203313490432"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>GS</given-names></name><name><surname>Dooley</surname><given-names>MA</given-names></name><name><surname>Treadwell</surname><given-names>EL</given-names></name><name><surname>St Clair</surname><given-names>EW</given-names></name><name><surname>Parks</surname><given-names>CG</given-names></name><name><surname>Gilkeson</surname><given-names>GS</given-names></name></person-group>. <article-title>Hormonal, environmental, and infectious risk factor for developing systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1998</year>; <volume>41</volume>: <fpage>1714</fpage>–<lpage>1724</lpage>.</citation></ref>
<ref id="bibr3-0961203313490432"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samanta</surname><given-names>A</given-names></name><name><surname>Feehally J</surname></name><name><surname>Roy S</surname></name><name><surname>Nichol FE</surname></name><name><surname>Sheldon PJ</surname></name><name><surname>Walls J</surname></name></person-group>. <article-title>High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>1991</year>; <volume>50</volume>: <fpage>490</fpage>–<lpage>492</lpage>.</citation></ref>
<ref id="bibr4-0961203313490432"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Yin</surname><given-names>G</given-names></name><name><surname>Mok</surname><given-names>MY</given-names></name></person-group>. <article-title>Ethnic and geographical differences in systemic lupus erythematosus: An overview</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>715</fpage>–<lpage>719</lpage>.</citation></ref>
<ref id="bibr5-0961203313490432"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilar</surname><given-names>MJ</given-names></name><name><surname>Sato</surname><given-names>EI</given-names></name></person-group>. <article-title>Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil)</article-title>. <source>Lupus</source> <year>2002</year>; <volume>11</volume>: <fpage>528</fpage>–<lpage>532</lpage>.</citation></ref>
<ref id="bibr6-0961203313490432"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilá</surname><given-names>LM</given-names></name><name><surname>Mayor</surname><given-names>AM</given-names></name><name><surname>Valentín</surname><given-names>AH</given-names></name><name><surname>García-Soberal</surname><given-names>M</given-names></name><name><surname>Vilá</surname><given-names>S</given-names></name></person-group>. <article-title>Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>1999</year>; <volume>8</volume>: <fpage>279</fpage>–<lpage>286</lpage>.</citation></ref>
<ref id="bibr7-0961203313490432"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsokos</surname><given-names>GC</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2011</year>; <volume>365</volume>: <fpage>2110</fpage>–<lpage>2121</lpage>.</citation></ref>
<ref id="bibr8-0961203313490432"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr9-0961203313490432"><label>9</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Peebles</surname><given-names>C</given-names></name></person-group> <article-title>Quantitation of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination</article-title>. In: <person-group person-group-type="editor"><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Friedman</surname><given-names>H</given-names></name></person-group> (eds). <source>Manual of clinical immunology</source>, <edition>2nd ed</edition>. <publisher-loc>Washington</publisher-loc>: <publisher-name>American Society of Microbiology</publisher-name>, <year>1980</year>, pp. <fpage>866</fpage>–<lpage>870</lpage>.</citation></ref>
<ref id="bibr10-0961203313490432"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurata</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>EM</given-names></name></person-group>. <article-title>Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis</article-title>. <source>Arthritis Rheum</source> <year>1976</year>; <volume>19</volume>: <fpage>574</fpage>–<lpage>580</lpage>.</citation></ref>
<ref id="bibr11-0961203313490432"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elkon</surname><given-names>KB</given-names></name><name><surname>Culhane</surname><given-names>L</given-names></name></person-group>. <article-title>Partial immunochemical characterization of the Ro and La proteins using antibodies from patients with the sicca syndrome and lupus erythematosus</article-title>. <source>J Immunol</source> <year>1984</year>; <volume>132</volume>: <fpage>2350</fpage>–<lpage>2356</lpage>.</citation></ref>
<ref id="bibr12-0961203313490432"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gharavi</surname><given-names>AE</given-names></name><name><surname>Harris</surname><given-names>EN</given-names></name><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Hughes</surname><given-names>GR</given-names></name></person-group>. <article-title>Anticardiolipin antibodies: Isotype distribution and phospholipid specificity</article-title>. <source>Ann Rheum Dis</source> <year>1987</year>; <volume>46</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation></ref>
<ref id="bibr13-0961203313490432"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>JT</given-names></name><name><surname>Triplett</surname><given-names>DA</given-names></name><name><surname>Alving</surname><given-names>B</given-names></name><name><surname>Scharrer</surname><given-names>I</given-names></name></person-group>. <article-title>Criteria for diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH</article-title>. <source>Thromb Haemost</source> <year>1995</year>; <volume>74</volume>: <fpage>1185</fpage>–<lpage>1190</lpage>.</citation></ref>
<ref id="bibr14-0961203313490432"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonfá</surname><given-names>E</given-names></name><name><surname>Golombek</surname><given-names>SJ</given-names></name><name><surname>Kaufman</surname><given-names>LD</given-names></name><etal/></person-group>. <article-title>Association between lupus psychosis and anti-ribosomal P protein antibodies</article-title>. <source>N Engl J Med</source> <year>1987</year>; <volume>317</volume>: <fpage>265</fpage>–<lpage>271</lpage>.</citation></ref>
<ref id="bibr15-0961203313490432"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senna</surname><given-names>ER</given-names></name><name><surname>De Barros</surname><given-names>AL</given-names></name><name><surname>Silva</surname><given-names>EO</given-names></name><etal/></person-group>. <article-title>Prevalence of rheumatic diseases in Brazil: A study using the COPCORD approach</article-title>. <source>J Rheumatol</source> <year>2004</year>; <volume>31</volume>: <fpage>594</fpage>–<lpage>597</lpage>.</citation></ref>
<ref id="bibr16-0961203313490432"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilá</surname><given-names>LM</given-names></name><name><surname>Mayor</surname><given-names>AM</given-names></name><name><surname>Valentín</surname><given-names>AH</given-names></name><etal/></person-group>. <article-title>Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus</article-title>. <source>P R Health Sci J</source> <year>1999</year>; <volume>18</volume>: <fpage>89</fpage>–<lpage>94</lpage>.</citation></ref>
<ref id="bibr17-0961203313490432"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pistiner</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>DJ</given-names></name><name><surname>Nessim</surname><given-names>S</given-names></name><name><surname>Metzger Al</surname></name><name><surname>Klineberg</surname><given-names>JR</given-names></name></person-group>. <article-title>Lupus erythematosus in the 1980s: A survey of 570 patients</article-title>. <source>Semin Arthritis Rheum</source> <year>1991</year>; <volume>21</volume>: <fpage>55</fpage>–<lpage>64</lpage>.</citation></ref>
<ref id="bibr18-0961203313490432"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>FJ</given-names></name><name><surname>de la Mata</surname><given-names>J</given-names></name><name><surname>Gómez-Reino</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Clinical and serological manifestations of 307 Spanish patients with systemic lupus erythematosus. Comparison with other ethnic groups [in Spanish]</article-title>. <source>Rev Clin Exp</source> <year>1995</year>; <volume>195</volume>: <fpage>534</fpage>–<lpage>540</lpage>.</citation></ref>
<ref id="bibr19-0961203313490432"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>MJ</given-names></name><name><surname>Capela</surname><given-names>S</given-names></name><name><surname>Figueira</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Characterization of a Portuguese population with systemic lupus erythematosus [in Portuguese]</article-title>. <source>Acta Reumatol Port</source> <year>2007</year>; <volume>32</volume>: <fpage>153</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr20-0961203313490432"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1000 patients</article-title>. <source>Medicine</source> <year>1993</year>; <volume>72</volume>: <fpage>113</fpage>–<lpage>124</lpage>.</citation></ref>
<ref id="bibr21-0961203313490432"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pons-Estel</surname><given-names>BA</given-names></name><name><surname>Catoggio</surname><given-names>LJ</given-names></name><name><surname>Cardiel</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>The GLADEL multinational Latin American prospective inception cohort of 1, 214 patients with systemic lupus erythematosus: Ethnic and disease heterogeneity among “Hispanics”</article-title>. <source>Medicine (Baltimore)</source> <year>2004</year>; <volume>83</volume>: <fpage>1</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr22-0961203313490432"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilá</surname><given-names>LM</given-names></name><name><surname>Alarcón</surname><given-names>GS</given-names></name><name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name><etal/></person-group>. <article-title>LUMINA Study Group. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations</article-title>. <source>Rheumatology (Oxford)</source> <year>2004</year>; <volume>43</volume>: <fpage>358</fpage>–<lpage>363</lpage>.</citation></ref>
<ref id="bibr23-0961203313490432"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chahade</surname><given-names>WH</given-names></name><name><surname>Sato</surname><given-names>EI</given-names></name><name><surname>Moura</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Costallat</surname><given-names>LT</given-names></name><name><surname>Andrade</surname><given-names>LE</given-names></name></person-group>. <article-title>Systemic lupus erythematosus in São Paulo/Brazil: A clinical and laboratory overview</article-title>. <source>Lupus</source> <year>1995</year>; <volume>4</volume>: <fpage>100</fpage>–<lpage>103</lpage>.</citation></ref>
<ref id="bibr24-0961203313490432"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>AlSaleh</surname><given-names>J</given-names></name><name><surname>Jassim</surname><given-names>V</given-names></name><name><surname>ElSayed</surname><given-names>M</given-names></name><name><surname>Saleh</surname><given-names>N</given-names></name><name><surname>Harb</surname><given-names>D</given-names></name></person-group>. <article-title>Clinical and immunological manifestations in 151 SLE patients living in Dubai</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>62</fpage>–<lpage>66</lpage>.</citation></ref>
<ref id="bibr25-0961203313490432"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group>. <article-title>Lupus in Hong Kong Chinese</article-title>. <source>Lupus</source> <year>2003</year>; <volume>12</volume>: <fpage>717</fpage>–<lpage>722</lpage>.</citation></ref>
<ref id="bibr26-0961203313490432"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al Arfaj</surname><given-names>AS</given-names></name><name><surname>Khalil</surname><given-names>N</given-names></name></person-group>. <article-title>Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>465</fpage>–<lpage>473</lpage>.</citation></ref>
<ref id="bibr27-0961203313490432"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Maini</surname><given-names>MH</given-names></name><name><surname>El-Ageb</surname><given-names>EM</given-names></name><name><surname>Al-Wahaibi</surname><given-names>SS</given-names></name><name><surname>Al-Farsi</surname><given-names>Y</given-names></name><name><surname>Richens</surname><given-names>ER</given-names></name></person-group>. <article-title>Demographic, autoimmune and clinical profiles of patients with systemic lupus erythematosus in Oman</article-title>. <source>Rheumatol Int</source> <year>2003</year>; <volume>23</volume>: <fpage>186</fpage>–<lpage>191</lpage>.</citation></ref>
<ref id="bibr28-0961203313490432"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houman</surname><given-names>MH</given-names></name><name><surname>Smiti-Khanfir</surname><given-names>M</given-names></name><name><surname>Ben Ghorbell</surname><given-names>I</given-names></name><name><surname>Miled</surname><given-names>M</given-names></name></person-group>. <article-title>Systemic lupus erythematosus in Tunisia: Demographic and clinical analysis of 100 patients</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>204</fpage>–<lpage>211</lpage>.</citation></ref>
<ref id="bibr29-0961203313490432"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burling</surname><given-names>F</given-names></name><name><surname>Ng</surname><given-names>J</given-names></name><name><surname>Thein</surname><given-names>H</given-names></name><name><surname>Ly</surname><given-names>J</given-names></name><name><surname>Marshall</surname><given-names>MR</given-names></name><name><surname>Gow</surname><given-names>P</given-names></name></person-group>. <article-title>Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: Results from a multi-ethinic New Zealand cohort</article-title>. <source>Lupus</source> <year>2007</year>; <volume>16</volume>: <fpage>830</fpage>.</citation></ref>
<ref id="bibr30-0961203313490432"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertoli</surname><given-names>AM</given-names></name><name><surname>Vilá</surname><given-names>LM</given-names></name><name><surname>Reveille</surname><given-names>JD</given-names></name><name><surname>Alarcón</surname><given-names>GS</given-names></name></person-group>. <collab>LUMINA study group</collab>. <article-title>Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) LIII: Disease expression and outcome in acute onset lupus</article-title>. <source>Ann Rheum Dis</source> <year>2008</year>; <volume>67</volume>: <fpage>500</fpage>–<lpage>504</lpage>.</citation></ref>
<ref id="bibr31-0961203313490432"><label>31</label><citation citation-type="other"><comment>Instituto Brasileiro de Geografia e Estatística. Síntese de Indicadores Sociais uma Análise das Condições de Vida da População Brasileira 2009, <ext-link ext-link-type="uri" xlink:href="http://www.ibge.gov.br/home/estatistica/populacao/condicaodevida/">http://www.ibge.gov.br/home/estatistica/populacao/condicaodevida/</ext-link>indicadoresminimos/sinteseindicsociais2009/indic_sociais2009.pdf (2009, accessed 2 May 2011)</comment>.</citation></ref>
<ref id="bibr32-0961203313490432"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>TC</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Magder</surname><given-names>LS</given-names></name><name><surname>Petri</surname><given-names>MA</given-names></name></person-group>. <article-title>Differences between male and female systemic lupus erythematosus in a multiethnic population</article-title>. <source>J Rheumatol</source> <year>2012</year>; <volume>39</volume>: <fpage>759</fpage>–<lpage>769</lpage>.</citation></ref>
<ref id="bibr33-0961203313490432"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>RM</given-names></name><name><surname>Alarcón</surname><given-names>GS</given-names></name><name><surname>Fernández</surname><given-names>M</given-names></name><name><surname>Reveille</surname><given-names>JD</given-names></name></person-group>. <collab>LUMINA Study Group</collab>. <article-title>Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort</article-title>. <source>Arthritis Rheum</source> <year>2007</year>; <volume>56</volume>: <fpage>622</fpage>–<lpage>630</lpage>.</citation></ref>
<ref id="bibr34-0961203313490432"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghirardello</surname><given-names>A</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Zampieri</surname><given-names>S</given-names></name><name><surname>Gerli</surname><given-names>R</given-names></name><name><surname>Rapizzi</surname><given-names>E</given-names></name><name><surname>Gambari</surname><given-names>PF</given-names></name></person-group>. <article-title>Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: Their specificity for SLE and association with IgG anticardiolipin antibodies</article-title>. <source>Ann Rheum Dis</source> <year>2000</year>; <volume>59</volume>: <fpage>975</fpage>–<lpage>981</lpage>.</citation></ref>
<ref id="bibr35-0961203313490432"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>M</given-names></name><name><surname>Kessenbrock</surname><given-names>K</given-names></name><name><surname>Szmyrka</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>International multicenter evaluation of autoantibodies to ribosomal P proteins</article-title>. <source>Clin Vaccine Immunol</source> <year>2006</year>; <volume>13</volume>: <fpage>77</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr36-0961203313490432"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname><given-names>E</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus?</article-title> <source>Clin Rev Allergy Immunol</source> <year>2007</year>; <volume>32</volume>: <fpage>37</fpage>–<lpage>46</lpage>.</citation></ref>
</ref-list>
</back>
</article>